Gilead, Merck and other big pharmas engaged in illicit “pay-for-delay” deals to retain their lucrative HIV and cholesterol meds supremacy

October 7, 2021

AstraZeneca commits $15 billion investment in China to advance radioconjugates and cell therapy innovation

February 4, 2026

Negative Confirmatory Study Results for Sarepta’s DMD Exon-Skippers

November 7, 2025

Must Read

AstraZeneca travels to China once more and purchases Dizal’s lung cancer medication for up to $1.5 billion

July 16, 2026

Spero Shells Out Over $1B For Innovent’s Autoimmune Antibody

July 16, 2026

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

July 16, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Sac-TMT and Keytruda Improve Progression-Free Survival in PD-L1-Negative NSCLC

Veradermics Reports Phase 2 Results for VDPHL01 in Women With Pattern Hair Loss

Dysport Meets Phase 3 Goals in Episodic and Chronic Migraine Trials

J&J Reports Positive Phase 2/3 Results for Imaavy in Warm Autoimmune Hemolytic Anemia

AstraZeneca travels to China once more and purchases Dizal’s lung cancer medication for up to $1.5 billion

Spero Shells Out Over $1B For Innovent’s Autoimmune Antibody

Insilico Joins Hands With CDMO Bora in AI Drug Discovery Deal Worth $2.5B

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

The Future of Smart Biopharmaceutical Manufacturing

Top 10 Risks Pharma Leaders Underestimate in AI Deployment

Top 10 Barriers to Scaling Genomics Programs in Healthcare

The Rise of AI-Native Biotech Companies

Tag: Biopharmaceutical

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

Editor Picks

Gilead, Merck and other big pharmas engaged in illicit “pay-for-delay” deals to retain their lucrative HIV and cholesterol meds supremacy

AstraZeneca commits $15 billion investment in China to advance radioconjugates and cell therapy innovation

Negative Confirmatory Study Results for Sarepta’s DMD Exon-Skippers

Must Read

AstraZeneca travels to China once more and purchases Dizal’s lung cancer medication for up to $1.5 billion

Spero Shells Out Over $1B For Innovent’s Autoimmune Antibody

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

Hot Topics

About Us

Follow Us